P3355
Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001Abiraterone in prostate cancer: a new angle to an old problemAbiraterone and increased survival in metastatic prostate cancer[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC-MS/MS-ESI: application to a pharmacokinetic study.Validated RP-HPLC/UV method for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats.Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.Abiraterone in prostate cancer.The role of abiraterone in the management of metastatic castration-resistant prostate cancer.Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.Abiraterone: current and future use in prostate cancer.Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancerClinical trial simulation to evaluate population pharmacokinetics and food effect: capturing abiraterone and nilotinib exposures.NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.NICE recommends abiraterone for prostate cancer after manufacturer reduces price.Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate CancerAbiraterone increases overall survival in men with castration-resistant prostate cancerSystemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic diseaseRisk of hypertension in Cancer patients treated with Abiraterone: a meta-analysisSystemic treatment for metastatic prostate cancerReduced T-cell Numbers and Elevated Levels of Immunomodulatory Cytokines in Metastatic Prostate Cancer Patients De Novo Resistant to Abiraterone and/or Enzalutamide TherapyThe LACOG-0415 phase II trial: abiraterone acetate and ADT versus apalutamide versus abiraterone acetate and apalutamide in patients with advanced prostate cancer with non-castration testosterone levelsUse of abiraterone for prostate cancerAbiraterone and MVD3100 take androgen deprivation to a new levelWords of wisdom. Re: Abiraterone and increased survival in metastatic prostate cancerAbiraterone. After prostate cancer treatment failure: 4-month survival advantageCombination therapy: Abiraterone prolongs survival in metastatic prostate cancerAbiraterone and increased survival in metastatic prostate cancerRole of androgens in abiraterone resistanceWords of wisdom. Re: Abiraterone and increased survival in metastatic prostate cancer
P921
Q24302773-6DCBAD24-E750-455D-B56A-A93B56396E42Q26828810-1908E413-5312-4623-AB82-DEAC7B2F80BDQ29617512-27d080db-4425-7400-801b-6ee9366f192cQ33399678-5FDDE431-32FF-411D-9058-CB4014C13619Q33752605-52BBA700-A249-4BC7-90BE-12D310BDB01FQ34048805-E148C516-5E08-4EDA-9175-AD64F6D33978Q34327168-5EA03314-54A5-44F4-A197-E3E5489A3135Q35209369-D13FB253-4037-45AE-BD65-DBDFE54CE451Q35249697-1D9974EE-83AD-4A07-8F3B-FA1F045CECF1Q37843409-9FA067D5-49F9-4BA3-9B06-6F12E3496B21Q38002465-55501140-7F8E-4F66-A51F-25F07D6D9F78Q39321170-2303EC2B-B305-4B9B-A457-36216D406B4CQ39380926-ED3EF439-DA0C-4428-A4AF-8A6E4DC75BB5Q39643293-A71BD56C-8775-4A39-AE78-38BC51441935Q41824448-AAAA6A7C-5EAA-498E-94AC-62CCC0A060ACQ42109132-EFBC691A-FA1B-4A25-B7A2-576D57933A6EQ45225792-A5084A8D-5346-49AC-9C4F-122B375E4B82Q48439950-16375F66-7D00-4099-9FB0-73D39A8DA869Q58068307-CA25FE46-6D52-46C1-872E-46E58CF01EA6Q62625976-A60A9055-68AE-4A3A-A757-3D22E4977291Q64089299-EA90D9AB-5FF2-43EB-9CBB-6ADFA389A9AEQ64090553-19D86463-5412-43A2-B3B5-1E32D01E1EECQ64236924-0512AA9B-3E8F-46B9-BACC-8EE8821C817CQ64254384-D9255F13-EA11-4D1E-9AFC-BAD089C4DD27Q64282468-20532E7D-C063-4DC3-A330-88DBCED24F86Q83215571-802BB964-4C04-4759-8D8D-F12A8D288801Q83223824-D905DF1E-721A-4BDF-A511-E4B0100FB968Q83531172-DA7165FD-EFF6-4C78-9824-5F2DD5630BC9Q84599074-BC267B63-5CE3-4865-9A39-0C5D2B19F3FBQ84639345-605488BD-BDD1-4057-977C-D1E8AF64E784Q84816499-D73C4EA1-1ABA-45B2-96B7-7F96EBD4041CQ84855748-5D38C4AD-7247-411C-B1E1-337BE128FCD0Q84857644-2407B68A-8F0E-4DA7-9C7B-6690C8E4E064
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Abirateron
@de
Abirateron
@et
Abirateron
@sh
Abirateron
@sr
Abiraterona
@es
Abiraterone
@nl
Abirateroniasetaatti
@fi
abirateron
@pl
abiraterone
@en
abiraterone
@it
type
label
Abirateron
@de
Abirateron
@et
Abirateron
@sh
Abirateron
@sr
Abiraterona
@es
Abiraterone
@nl
Abirateroniasetaatti
@fi
abirateron
@pl
abiraterone
@en
abiraterone
@it
altLabel
(3beta)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol
@en
(3β)-17-(pyridin-3-yl)androsta-5,16-dien-3-ol
@en
17-(3-pyridyl)androsta-5,16-dien-3beta-ol
@en
CB 7598
@en
prefLabel
Abirateron
@de
Abirateron
@et
Abirateron
@sh
Abirateron
@sr
Abiraterona
@es
Abiraterone
@nl
Abirateroniasetaatti
@fi
abirateron
@pl
abiraterone
@en
abiraterone
@it